Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
NN9925 · 1 trial · 3 indications
| Arm | Type | Description |
|---|---|---|
| Trial part 1 | EXPERIMENTAL | - |
| Trial part 2 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| NN9925 (oral) | DRUG | Subjects will be randomised to receive a single dose of NN9925, at escalating dose levels. Progression to next dose will be based on safety evaluation |
| NN9925 (i.v.) | DRUG | As an active comparator, one standard dose will be given i.v. (into the vein) at one study visit |
| placebo | DRUG | Subjects will receive a single dose of placebo as a comparator to NN9925, at all dose levels |
Inclusion Criteria: * Male subjects with good general health as judged by the physician * Body weight of 65-95 kg (both inclusive) * Body Mass Index (BMI) of 18.5-27.5 kg/m2 (both inclusive) Exclusion Criteria: * Known or suspected allergy to trial product or related products * Acute infection or...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| FibroBiologics, Inc. | FBLG | 1 | PHASE1 | Undisclosed |
| MiMedx Group, Inc. | MDXG | 2 | N/A | Undisclosed |
| Integra LifeSciences Holdings Corporation | IART | 1 | N/A | Undisclosed |
| Organogenesis Holdings, Inc. Class A | ORGO | 1 | N/A | Undisclosed |
| Healthcare Services Group, Inc. | HCSG | 1 | N/A | Undisclosed |
NN9925 is an investigational small molecule being developed for diabetes, including type 2 diabetes. It is currently in Phase 1 clinical development and is not yet approved. The drug is being studied for its safety and tolerability in healthy subjects.
NN9925 is a small molecule being developed for diabetes. Its specific molecular target has not been disclosed in available information. The drug is in Phase 1 clinical trials to evaluate its safety and tolerability.
NN9925 is being developed by Novo Nordisk A/S, a pharmaceutical company listed on the stock exchange under the ticker NVO. The drug is currently in Phase 1 clinical development for diabetes.
NN9925 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. One Phase 1 trial has been completed, and the drug is being studied for diabetes.
NN9925 has one completed Phase 1 clinical trial, NCT01087645, titled 'A Two Part Trial Investigating the Safety of NN9925 in Healthy Male Subjects.' The trial enrolled 70 healthy male participants in the United Kingdom and was a randomized, double-blind, controlled study.
No alternative names for NN9925 have been disclosed. The drug is being developed by Novo Nordisk A/S under the code name NN9925 and is currently in Phase 1 clinical trials for diabetes.